Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, \>=12 years of age.~* Severe hemophilia A or B without inhibitors.~  * Severity confirmed by a central laboratory where FVIII level was less than (\<) 1 percent (%) or Factor IX (FIX) level was less than or equal to (\<=) 2% at Screening.~ * On-demand use of factor concentrate to manage bleeding episodes for at least the last 6 months prior to Screening, and meet each of the following criterion:~    * Nijmegen modified Bethesda assay inhibitor titer of \<0.6 Bethesda units per milliliter (BU/mL) at Screening.~   * No use of Bypassing agents to treat bleeding episodes for at least the last 6 months prior to Screening.~   * No history of immune tolerance induction therapy within the last 3 years prior to Screening.~* A minimum of 6 bleeding episodes requiring factor concentrate treatment within the last 6 months prior to Screening.~* Willing and complied with the study requirements and to provide written informed consent and assent.~Exclusion Criteria:~* Known co-existing bleeding disorders other than hemophilia A or B, i.e., Von Willebrand's disease, additional factor deficiencies, or platelet disorders.~* Antithrombin (AT) activity \<60% at Screening.~* Co-existing thrombophilic disorder.~* Clinically significant liver disease.~* Active hepatitis C virus infection.~* HIV positive with a cluster of differentiation-4 count of \<200 cells/microliter.~* History of arterial or venous thromboembolism.~* Inadequate renal function.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc).~* History of intolerance to SC injection(s).~* Any other conditions or comorbidities that would make the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Factor On-demand (Type: EXPERIMENTAL): Participants received on-demand factor concentrates (as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion for the treatment of breakthrough bleeding episodes from Day 1 up to a total of 9 months.
- Fitusiran 80 mg Prophylaxis (Type: EXPERIMENTAL): Participants received open-label fitusiran 80 milligram (mg) administered subcutaneously (SC) as prophylaxis once monthly from Day 1 up to a total of 9 months. Participants received on-demand factor concentrates (per investigator's discretion and within bleeding dosing guidelines) for the treatment of breakthrough bleeding episodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).